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Abstract: West Nile virus (WNV) is a mosquito-borne virus of global importance. Over 
the last two decades, it has been responsible for significant numbers of cases of illness in 
humans and animals in many parts of the world. In Ukraine, WNV infections in humans 
and birds were first reported more than 25 years ago, yet the current epidemiological status 
is quite unclear. In this study, serum samples from over 300 equines were collected and 
screened in order to detect current WNV activity in Ukraine with the goal to estimate the 
risk of infection for humans and horses. Sera were tested by enzyme-linked 
immunosorbent assay (ELISA) and virus neutralization assay (NT) to detect WNV-specific 
antibodies. The results clearly revealed that WNV circulates in most of the regions from 
which samples were obtained, shown by a WNV seroprevalence rate of 13.5% of examined 
horses. This is the first topical report indicating the presence of WNV infections in horses 
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in Ukraine, and the results of this study provide evidence of a widespread WNV circulation 
in this country. 




West Nile virus (WNV) is an arbovirus that is maintained in an enzootic cycle between 
ornithophilic mosquitoes and certain wild bird species. WNV is the most widespread flavivirus known, 
was first isolated in Uganda in 1937, and has been found on all continents [1,2], except for Antarctica. 
Distinct wild bird species serve as major reservoir hosts, although even under natural conditions a 
variety of mammalian and reptilian species are susceptible [3]. Likewise, a variety of different bird and 
mosquito species are involved in the WNV life cycle in various regions of the world [4]. WNV 
infections in humans and equines can lead to febrile illness, which in some cases will progress to 
encephalitis, occasionally with fatal outcome [5]. Outside of the African continent, WNV usually 
causes clinical cases only sporadically in humans and equines in Mediterranean countries, the Middle 
East, Romania and Russia [1,6-8]. WNV encephalitis cases were first reported in humans and horses in 
the Camargue region of France in the early 1960s [9] and WNV has since been observed repeatedly in 
the central part of Europe [10]. Until the mid1990s, WNV was considered a minor risk for humans and 
horses as — with some regional exceptions — it occurred only sporadically [11]. The first major WNV 
epidemic in Eastern Europe was observed in Romania in 14 districts of the lower Danube valley and in 
Bucharest with more than 400 clinical cases in 1996 [6]. In the late 1990s, outbreaks of WNV fever 
with high numbers of infected humans were also observed in Israel and southern Russia [12]. WNV 
infections became a major concern for veterinary public health after its introduction into the New 
World and rapidly spread to almost all countries on the American continent over the following years 
[13]. Large WNV outbreaks affecting humans and equines have been reported most recently in Greece 
[14], and WNV lineage 2 sequences could be demonstrated in human blood donors, Culex mosquitoes, 
wild birds and sentinel chickens. In the summer of 2012, evidence of WNV circulation was also found 
in Slovakia [15] and in various Balkan countries, including Serbia, Kosovo, Macedonia and Croatia 
[16]. Major outbreaks in humans and horses have also been observed over the past few years in the 
Mediterranean area, e.g. in Italy; however, preferentially WNV lineage 1 sequences have been detected 
[17]. Recently, WNV lineage 2 viruses have also been detected in wild birds in Sardinia [18] and in 
northeastern Italy.   
In Ukraine, the earliest reports confirming the presence of WNV infections in humans and birds 
date back to the 1970s. In 1974, Sidenko et al. [19] described human WNV infections and the 
accompanying neurological signs, as well as WNV specific antibodies in wild birds and farm animals 
in the southwestern USSR. In 1985, 38 human cases, 16 of them with neurological manifestations, 
were recorded in the Transcarpathian region (Ukrainian SSR). The course of disease was benign [20]. 
At the same time (1980s), a WNV strain was detected in the blood and internal organs of a wild bird 
(Rook, Corvus frugileus) in the territory of the Black Sea [21]. A recently conducted study on 




arbovirus infections showed new active natural foci in the forest-steppe zone of Ukraine and a close 
etiological relation was found between acute seasonal febrile diseases and the above-mentioned 
arbovirus. Besides tick-borne encephalitis, WNV disease, therefore, is the leading arboviral infection 
in the forest-steppe zone of Ukraine [22].  
Recently, clinical WNV infections have been detected in patients in Ukraine in the summer of 2011 
(eight WNV cases in three different regions/oblasts) and in 2012 (12 human cases in one region 
(Poltavska)) [23-25]. However, little is known about the extent of WNV infections in horses in 
Ukraine at present. The aim of the monitoring study (two-year-analysis) presented here was to 
investigate the prevalence of WNV specific antibodies in horse sera from 14 different Ukrainian 
regions (oblasts) by means of enzyme-linked immunosorbent assay (ELISA) and virus neutralization 
assays (NT). The results provide relevant information on the current WNV situation in Ukraine, 
involving an infection risk for humans and horses. 
2. Results and Discussion 
Horse sera from 310 animals kept in 14 different Ukrainian regions were collected in 2010 and 
2011 (Figure 1, Table 1). Sera were screened by a commercial WNV competition ELISA, which 
essentially detects flavivirus antibodies. Therefore ELISA-positive results were verified by virus 
neutralization tests (NT) to identify WNV or cross-reactivity specific reactions.  
 
Figure 1. Sampling sites of the horse sera with focus on known WNV risk areas. 
 

















1 Donetska 11 11  - 
2 Kharkivska 21 21  - 
3 Khmelnytska 39 38 1 
4 Kyivska 118 113 5 
5 Kirovohradska 59 52 7 
6 Luhanska 20 20  - 
7 Odeska 1 1  - 
8 Poltavska 6 6  - 
9 Rivnenska 13 11 2 
10 Sumska 2 2  - 
11 Vinnytska 2 2  - 
12 Volynska 10 10  - 
13 Zaporizka 6 6  - 
14 Zhytomyrska 2 2  - 
 
Total   310 295 15 
 
2.1. WNV competition Enzyme-linked immunosorbent assay (ELISA). 
From the 310 sera, 295 samples were investigated using the competitive WNV ELISA. Volumes of 
the remaining 15 samples were so low (<50 µl) that they were only used for different NT (Table 1). 
The ELISA results showed a high rate of seropositive horses in different regions of Ukraine (Table 2). 
A total of 49 out of the 295 sera were reactive (Figure 2). Resulting in an overall ELISA prevalence 
rate of 16.6%., WNV antibody-positive animals were discovered in seven of the 14 investigated 
Ukrainian regions and high ELISA prevalence rates between 20% and 25% were determined for the 
Luhanska, Kharkivska and Kirovohradska regions. Even higher prevalence rates were obtained for 
Poltavska (33%) and Zaporizka (83%), with the caveat, however, that available sample numbers were 
small (n=6) (Table 2). All 49 ELISA-positive samples were investigated further by the different NT to 
exactly determine the virus resulting in ELISA seropositivity. 
Table 2. Competitive ELISA results stratified by region and regional antibody prevalence. 









1 Donetska 11 11  -  - 




2 Kharkivska 21 16 5 23.80 % 
3 Khmelnytska 38 37 1 2.63 % 
4 Kyivska 113 94 19 16.81 % 
5 Kirovohradska 52 39 13 25.00 % 
6 Luhanska 20 16 4 20.00 % 
7 Odeska 1 1  -  - 
8 Poltavska 6 4 2 33.33 % 
9 Rivnenska 11 11  -  - 
10 Sumska 2 2  -  - 
11 Vinnytska 2 2  -  - 
12 Volynska 10 10  -  - 
13 Zaporizka 6 1 5 83.33 % 
14 Zhytomyrska 2 2  -  - 
 
Total   295 246 49 16.61 % 
 
Figure 2. Competitive ELISA (S/N%) results of all 295 investigated horse sera. (1 = 
reactive samples, 2 = negative samples) 
 
  




2.2. Virus neutralization assays (NT) 
 
ELISA results were generally confirmed by NT results. In total, 68 horse sera (49 initially ELISA 
positive sera plus the 15 sera of which only small volumes were available and four additional sera, 
randomly selected) were investigated in a WNV neutralization assay. The ELISA results were 
confirmed for 42 out of the 49 ELISA-positive sera by WNV-NT, with neutralization titers ranging 
between 1:10 and 1:640 (Table 3). From the 15 sera with small volumes for which no ELISA results 
were available, three sera contained WNV-specific antibodies. One sample was excluded due to serum 
toxicity for cells.    
Another seven sera with positive ELISA and negative WNV-NT results, as well as all sera with 
weak positive and positive WNV-NT results, were eventually run in a tick-borne encephalitis virus 
neutralization test (TBEV-NT) to check for cross-reactivity. False positive ELISA results caused by 
TBE cross-reactive antibodies had been observed in earlier serological studies looking at horses from 
Germany and Austria [26-28] which impede the interpretation of the ELISA results. However, no 
TBEV-NT positive horse serum was found among the Ukrainian horse sera (Table 3). Although 
Lozyns'kyĭ and Vynohrad (1998 [22]) described the occurrence and wide distribution of tick-borne 
encephalitis in the forest-steppe zone of Ukraine, our sample panel revealed no incidence of a TBEV 
infection. 
  
2.3. Indirect WNV IgM ELISA 
 
ELISA-positive sera with clear NT negative or weak positive NT results, as well as sera, of which 
only small sample volumes (< 50µl) were available, were also run in a commercially available IgM 
ELISA to detect recent WNV infections. This capture ELISA detects WNV specific IgM antibodies in 
horse sera for up to 3 months post infection. However, none of the 23 investigated samples contained 
WNV IgM antibodies (data not shown). Therefore there was no evidence for recent WNV infections in 
these samples. 
  
Table 3.  ELISA and neutralization assay results of 68 horse samples. (* not enough serum 

















ELISA and WNV-NT positive (n=42) 
33 14.19% positive  10 weak positive < 10 negative 
44 12.28% positive  15 weak positive < 10 negative 
53 6.18% positive  60 positive < 10 negative 
54 4.98% positive  480 positive < 10 negative 
58 6.35% positive  640 positive < 10 negative 
59 5.09% positive  320 positive < 10 negative 




64 4.73% positive  640 positive < 10 negative 
68 4.94% positive  160 positive < 10 negative 
69 4.87% positive  640 positive < 10 negative 
71 4.98% positive  240 positive < 10 negative 
72 4.83% positive  160 positive < 10 negative 
75 5.90% positive  30 positive < 10 negative 
88 5.53% positive  40 positive < 10 negative 
96 5.97% positive  40 positive < 10 negative 
97 4.91% positive  160 positive < 10 negative 
105 5.77% positive 60 positive < 10 negative 
107 4.73% positive  160 positive < 10 negative 
108 4.67% positive  160 positive < 10 negative 
123 7.86% positive  80 positive < 10 negative 
124 4.81% positive  80 positive < 10 negative 
128 4.15% positive  160 positive < 10 negative 
131 3.88% positive  80 positive < 10 negative 
146 8.79% positive  15 weak positive < 10 negative 
149 4.31% positive  20 positive < 10 negative 
158 4.04% positive  80 positive < 10 negative 
160 3.78% positive  320 positive < 10 negative 
166 4.55% positive  120 positive < 10 negative 
187 4.63% positive  180 positive < 10 negative 
208 6.09% positive  10 weak positive < 10 negative 
217 7.84% positive  30 positive < 10 negative 
228 4.44% positive  120 positive < 10 negative 
232 10.92% positive  10 weak positive < 10 negative 
288 4.48% positive  320 positive < 10 negative 
289 9.16% positive  60 positive < 10 negative 
292 5.09% positive  40 positive < 10 negative 
297 5.35% positive  480 positive < 10 negative 
312 5.12% positive  60 positive < 10 negative 
313 4.92% positive  160 positive < 10 negative 
330 7.98% positive  80 positive < 10 negative 
336 4.18% positive  120 positive < 10 negative 
337 4.44% positive  160 positive < 10 negative 
343 7.08% positive  10 weak positive < 10 negative 
ELISA positive and WNV-NT negative (n=7) 
98 34.70% positive < 10 negative < 10 negative 
106 26.64% positive < 10 negative < 10 negative 
183 14.07% positive < 10 negative < 10 negative 




230 23.58% positive < 10 negative < 10 negative 
250 30.98% positive < 10 negative < 10 negative 
295 25.88% positive < 10 negative < 10 negative 
328 39.16% positive < 10 negative < 10 negative 
ELISA negative and WNV-NT positive (n=4) 
209 91.31% negative  30 positive < 10 negative 
210 86.89% negative  120 positive < 10 negative 
212 90.21% negative  10 weak positive < 10 negative 
214 93.03% negative  320 positive < 10 negative 
Low volume  no ELISA, WNV-NT positive (n=3) 
126 n.d. *  80 positive < 10 negative 
127 n.d. *  60 positive < 10 negative 
162 n.d. *  60 positive < 10 negative 
Low volume  no ELISA, WNV-NT negative (n=11+1 not evaluable) 
27 n.d. * < 10 negative < 10 negative 
76 n.d. * < 10 negative < 10 negative 
100 n.d. * not evaluable, because of serum toxicity for cells 
125 n.d. * < 10 negative < 10 negative 
129 n.d. * < 10 negative < 10 negative 
130 n.d. * < 10 negative < 10 negative 
138 n.d. * < 10 negative < 10 negative 
139 n.d. * < 10 negative < 10 negative 
163 n.d. * < 10 negative < 10 negative 
179 n.d. * < 10 negative < 10 negative 
180 n.d. * < 10 negative < 10 negative 
186 n.d. * < 10 negative < 10 negative 
 
In summary, our results show that WNV circulates in large parts of Ukraine. In total, 42 horse sera 
(Table 3) tested positive for WNV antibodies as determined by both ELISA and NT. These samples 
were collected in seven regions, namely Kharkivska, Khmelnytska, Kyivska, Kirovohradska, 














Figure 3. Number of WNV positive sera (red columns = both in ELISA and NT) in horses 




Table 4.  Distribution of the ELISA and NT positive samples. 
 
Ukraine region 
comp. ELISA positive 
and  WNV-NT positive 
WNV-NT   
ND50 titres 
1 Donetska  -  - 
2 Kharkivska 4 10 - 160 
3 Khmelnytska 1 10 
4 Kyivska 17 10 - 640 
5 Kirovohradska 11 30 - 160 
6 Luhanska 3 15 - 120 
7 Odeska  -  - 
8 Poltavska 1 40 
9 Rivnenska  -  - 
10 Sumska  -  - 
11 Vinnytska  -  - 
12 Volynska  -  - 
13 Zaporizka 5 60 - 480 
14 Zhytomyrska  -  - 
   42   




The overall findings reported here are consistent with those from previous WNV seroprevalence 
studies in horses, mosquitoes and wild birds [7,19,21,29,30] and humans [19,20,29] in Ukraine. Most 
recently, high infection rates have also been found in humans in Romania and the Russian Federation, 
which are immediate neighbors of Ukraine [6,12]. Large parts of the Ukrainian landscape (rivers, 
wetlands and lowlands) and the country`s climatic conditions (wet winters and springs followed by 
excessive heat in the summers) are commensurate with environmental conditions necessary for 
productive circulation of WNV in wildlife. Moreover, Ukraine is located on major migratory bird 
flyways connecting Africa and The Middle East with Eurasia [31]. WNV endemics establish 
themselves particularly in urban regions with open water drainage systems and improper basic 
sanitation [32]. During the time of sampling, no clinical WNV cases were reported in horses, whereas 
clinical cases were confirmed in humans in 2011 and 2012 in Ukraine [23-25].  
To exclude serological cross-reactions leading to false WNV seropositivity, differential diagnostic 
assays were conducted. As the WNV ELISA used also detects cross-reacting antibodies induced by 
other flaviviruses, e.g. TBEV [26-28], all sera negative in the WNV NT were also screened using a 
TBEV NT (Table 3) as well as a Japanese encephalitis virus (JEV) NT, all with negative outcomes 
(data not shown). The reason for ELISA reactivity of the seven sera (positive WNV ELISA, but 
negative in all conducted NTs, Table 3) is unclear at present. Besides measuring different properties of 
antibodies in the assay systems, this may indicate circulation of an as-yet-unknown flavivirus in 
Ukraine.  
3. Experimental Materials and Methods 
Serum samples. Blood samples were collected from 310 randomly selected healthy horses, which 
were kept in 14 regions of Ukraine during 2010 and 2011 (Table 1). Horses had no known clinical 
history of a previous WNV infection. Sera were kept at –20 ºC until use.  
ELISA. Sera were screened for WNV specific antibodies using a commercially available 
competition ELISA, which allows the species-independent recognition of WNV antibodies against the 
PrM- and E envelope protein (ID Screen® West Nile Competition, IDVet, Montpellier, France). The 
ELISA cut-off is defined by the residual binding ratios (S/N%-value); sera with S/N ratios of 40% and 
lower are positive, while samples with S/N ratios of more than 50 are considered WNV  
antibody-negative. S/N values of 40–50% are inconclusive. Additionally, a commercially available 
IgM capture ELISA was used (IDEXX IgM WNV Ab Test, IDEXX Europe B.V., Hoofddorp, the 
Netherlands) to detect recent WNV infection in horses. 
NT. ELISA results were confirmed by virus neutralization test carried out under biosafety level 3 
conditions and using Vero cells on 96-well plates as described earlier [33]. Test serum dilutions (20 µl 
starting heat-inactivated serum material) were pre-incubated with 100 TCID50 of WNV strain Austria 
(lineage 2, Accession no. HM015884, kindly provided by Dr. N. Nowotny, Institute of Virology, 
University of Veterinary Medicine, Vienna). All samples were run in duplicate and NT titers were 
calculated after inspection of the assay at 6 to 7 days after infection, depending on the cytopathic 
effects in the infected control wells. The neutralizing antibody titer was defined as the neutralization 
dose 50% (ND50), i.e. the maximum dilution, which inhibited cytopathic effects in 50% of the wells 
according to the Behrens-Kaerber method. ND50 values of above 10 were considered positive. The 




TBEV serum neutralization test was carried out following the same protocol, except that the TBEV 
strain Neudoerfl (kindly provided by Dr. F. Hufert, Institute for Virology, Göttingen Germany; 
GenBank accession no. U27495) was used. Furthermore, JEV-NT was carried out using the same 
procedure and using JEV strain Nakayama (GenBank accession no. EF571853). 
Maps. GIS-Analysis of the sampling sites and of the results was performed by using the ArcGIS 
Arview 10.0 software (ESRI, Redlands, CA, USA) and displayed using a Lambert conformal conic 
coordinate system. 
4. Conclusions  
WNV specific antibodies were detected in sera from horses originating from seven Ukrainian 
regions, thus representing a substantial part of the country’s territory (Figure 1), and the mean  
sero-prevalence rate for WNV was 13.5% indicating an existing infection occasion. However, IgM 
ELISA analyses on selective sera did not reveal any evidence of recent infections. Samples were 
unsuitable for the demonstration of WNV genomes. 
This is the first up-to-date report indicating WNV infections prevalence in horses in Ukraine, and 
these results provide evidence of widespread WNV circulation in this country. The results will help to 
determine the risk of infection for humans and to control WNV transmission. Surveillance studies in 
humans, vectors and animals are needed to better define endemic areas.  
Acknowledgments 
We thank Tobias Winterfeld and Cornelia Steffen for their excellent technical assistance. This study 
was partially funded by NADIR and by EU grant FP7-261504 EDENext and is catalogued by the 
EDENext Steering Committee as EDENext181 (http://www.edenext.eu). The contents of this 
publication are the sole responsibility of the authors and don`t necessarily reflect the views of the 
European Commission.    
Conflict of Interest 
The authors declare no conflict of interest.  
References and Notes 
1. Calistri, P.; Giovannini, A.; Hubalek, Z.; Ionescu, A.; Monaco, F.; Savini, G.; Lelli, R. 
Epidemiology of West Nile in europe and in the Mediterranean basin. Open Virol. J. 2010, 4, 
29-37. 
2. Weissenbock, H.; Hubalek, Z.; Bakonyi, T.; Nowotny, N. Zoonotic mosquito-borne 
flaviviruses: worldwide presence of agents with proven pathogenicity and potential candidates 
of future emerging diseases. Vet. Microbiol. 2010, 140, 271-280. 
3. van der Meulen, K.M.; Pensaert, M.B.; Nauwynck, H.J. West Nile virus in the vertebrate 
world. Arch. Virol. 2005, 150, 637-657. 
4. Turell, M.J. Members of the Culex pipiens complex as vectors of viruses. J. Am. Mosq. Control 
Assoc. 2012, 28, 123-126. 




5. Garcia-Bocanegra, I.; Jaen-Tellez, J.A.; Napp, S.; Arenas-Montes, A.; Fernandez-Morente, M.; 
Fernandez-Molera, V.; Arenas, A. West Nile fever outbreak in horses and humans, Spain, 
2010. Emerg. Infect. Dis. 2011, 17, 2397-2399. 
6. Tsai, T.F.; Popovici, F.; Cernescu, C.; Campbell, G.L.; Nedelcu, N.I. West Nile encephalitis 
epidemic in southeastern Romania. Lancet 1998, 352, 767-771. 
7. Hubalek, Z. Mosquito-borne viruses in Europe. Parasitol. Res. 2008, 103 Suppl 1, S29-43. 
8. Lvov, D.K.; Butenko, A.M.; Gromashevsky, V.L.; Kovtunov, A.I.; Prilipov, A.G.; Kinney, R.; 
Aristova, V.A.; Dzharkenov, A.F.; Samokhvalov, E.I.; Savage, H.M., et al. West Nile virus and 
other zoonotic viruses in Russia: examples of emerging-reemerging situations. Arch. Virol. 
Suppl. 2004, 85-96. 
9. Murgue, B.; Murri, S.; Zientara, S.; Durand, B.; Durand, J.P.; Zeller, H. West Nile outbreak in 
horses in southern France, 2000: the return after 35 years. Emerg. Infect. Dis. 2001, 7, 692-696. 
10. Pfeffer, M.; Dobler, G. Emergence of zoonotic arboviruses by animal trade and migration. 
Parasit. Vectors 2010, 3, 35. 
11. De Filette, M.; Ulbert, S.; Diamond, M.; Sanders, N.N. Recent progress in West Nile virus 
diagnosis and vaccination. Vet. Res. 2012, 43, 16. 
12. Lvov, D.K.; Butenko, A.M.; Gromashevsky, V.L.; Larichev, V.P.; Gaidamovich, S.Y.; 
Vyshemirsky, O.I.; Zhukov, A.N.; Lazorenko, V.V.; Salko, V.N.; Kovtunov, A.I., et al. 
Isolation of two strains of West Nile virus during an outbreak in southern Russia, 1999. Emerg. 
Infect. Dis. 2000, 6, 373-376. 
13. Komar, N. West Nile virus: epidemiology and ecology in North America. Adv Virus Res 2003, 
61, 185-234. 
14. Papa, A. West Nile virus infections in Greece: an update. Expert Rev. Anti Infect. Ther. 2012, 
10, 743-750. 
15. Hubalek, Z.; Ludvikova, E.; Jahn, P.; Treml, F.; Rudolf, I.; Svobodova, P.; Sikutova, S.; 
Betasova, L.; Bires, J.; Mojzis, M., et al. West Nile Virus Equine Serosurvey in the Czech and 
Slovak Republics. Vector Borne Zoonotic Dis. 2013, [Epub ahead of print]. 
16. Promedmail: Archive Number: 20120921.1304610 Available online: 
http://www.promedmail.org  (accessed on 13.08.2013). 
17. Monaco, F.; Savini, G.; Calistri, P.; Polci, A.; Pinoni, C.; Bruno, R.; Lelli, R. 2009 West Nile 
disease epidemic in Italy: first evidence of overwintering in Western Europe? Res. Vet. Sci. 
2011, 91, 321-326. 
18. Savini, G.; Puggioni, G.; Di Gennaro, A.; Di Francesco, G.; Rocchigiani, A.M.; Polci, A.; 
Marini, V.; Pinoni, C.; Rolesu, S.; Marruchella, G., et al. West Nile virus lineage 2 in Sardinian 
wild birds in 2012: a further threat to public health. Epidemiol. Infect. 2013, 1-4. 
19. Sidenko, V.P.; Stepankovskaia, L.D.; Solomko, R.M.; Poliakov, E.M.; Grekov, V.S.; Mosketi, 
K.B.; Scharanova, O.K.; Alekseenko, O.A.; Woljanskaia, E.A.; Fiadina, D.D. [Results of a 
study of West Nile fever in the South of the European part of the USSR]. Zh. Mikrobiol. 
Epidemiol. Immunobiol. 1974, 00, 129. 
20. Buletsa, B.A.; Turak Iu, A.; Korol, M.; Ignatovich, II; Vitvitskii, A.A. [Neurologic 
manifestations of West Nile fever in the Transcarpathian region]. Zh. Nevropatol. Psikhiatr. Im. 
S. S. Korsakova 1989, 89, 29-30. 




21. Vinograd, I.A.; Beletskaia, G.V.; Chumachenko, S.S.; Ardamatskaia, T.B.; Rogochii, E.G.; 
Lutsik, B.D.; Palchevski, N.V.; Vigovksy, A.I.; Olmelchenko, A.A. [Isolation of West Nile 
virus in the Southern Ukraine]. Vopr. Virusol. 1982, 27, 567-569. 
22. Lozyns'kyi, I.M.; Vynohrad, I.A. [Arboviruses and arbovirus infections in the forest steppe 
zone of Ukraine]. Mikrobiol. Z. 1998, 60, 49-60. 
23. ECDC, European Centers for Disease Prevention and Control: West Nile Fever Map - Table on 
cases 2011. Available online: http://ecdc.europa.eu/en/healthtopics/west_nile_fever/West-Nile-
fever-maps/Pages/2010-table.aspx (accessed on August 13 2013). 
24. ECDC, E.C.f.D.P.a.C.: West Nile Fever Map - Table on cases 2012. Available online: 
http://ecdc.europa.eu/en/healthtopics/west_nile_fever/West-Nile-fever-maps/Pages/2012-
table.aspx (accessed on August 13 2013). 
25. Giese, C.; Ait el Belghiti, F.; Barboza, P. and all National EpiSouth Focal Points: West Nile 
Virus Circulation in the EpiSouth countries and neighbouring areas, Seasons 2010 and 2011. 
Update 1st July 2012. Available online: http://www.episouthnetwork.org/sites/ 
default/files/outputs/note_west_nile_episouth_2010_2011_july2012.pdf (accessed on August 
13 2013). 
26. Ziegler, U.; Seidowski, D.; Angenvoort, J.; Eiden, M.; Müller, K.; Nowotny, N.; Groschup, 
M.H. Monitoring of West Nile virus infections in Germany. Zoon. Public Health 2012, 59 
Suppl 2, 95-101. 
27. Rushton, J.O.; Lecollinet, S.; Hubalek, Z.; Svobodova, P.; Lussy, H.; Nowotny, N. Tick-borne 
Encephalitis Virus in Horses, Austria, 2011. Emerg. Infect. Dis. 2013, 19, 635-637. 
28. Ziegler, U.; Angenvoort, J.; Klaus, C.; Nagel-Kohl, U.; Sauerwald, C.; Thalheim, S.; Horner, 
S.; Braun, B.; Kenklies, S.; Tyczka, J., et al. Use of competition ELISA for monitoring of west 
nile virus infections in horses in Germany. Int. J. Environ. Res. Public Health 2013, 10, 3112-
3120. 
29. Hubalek, Z.; Halouzka, J. West Nile fever - a reemerging mosquito-borne viral disease in 
Europe. Emerg. Infect. Dis. 1999, 5, 643-650. 
30. Vinograd, I.A.; Beletskaia, G.V.; Chumachenko, S.S.; Omelchenko, G.A.; Lozinski, I.N.; 
Yartys, O.S., et al. [Ecological aspects of arbovirus studies in the Ukrainian SSR]. In [Ecology 
of viruses and diagnostics of arbovirus infections.], Lvov, D.K.; Gaidamovich, S.Y., Eds. Acad 
Med Sci USSR: Moscow, 1989; pp 21 - 27. 
31. Atkinson, P.W.; Clark, J.A.; Delany, S.; Diagana, C.H.; du Feu, C.; Fiedler, W.; Fransson, T.; 
Gaulthier-Clerc, M.; Grantham, M.; Gschweng, M., et al.: Urgent preliminary assessment of 
ornithological data relevant to the spread of Avian Influenza in Europe. Report to the European 
Commission. May 2006. Available online: http://ec.europa.eu/environment/ 
nature/conservation/wildbirds/birdflue/index_en.htm (accessed on August 18 2013). 
32. Reiter, P. West Nile virus in Europe: understanding the present to gauge the future. Euro 
surveillance : bulletin Européen sur les maladies transmissibles = European communicable 
disease bulletin. 2010, 15, 19508. 
 




33. Seidowski, D.; Ziegler, U.; von Rönn, J.A.; Müller, K.; Hüppop, K.; Müller, T.; Freuling, C.; 
Mühle, R.U.; Nowotny, N.; Ulrich, R.G., et al. West Nile virus monitoring of migratory and 
resident birds in Germany. Vector Borne Zoonotic Dis. 2010, 10, 639-647. 
© 2013 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/3.0/). 
 
